SA Asks: Which biotechs are most likely to be acquired near-term?

Last year’s first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.

Other major deals announced before the end of the quarter included Gilead (